Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Oral TAK-788 DDI with Itraconazole and Rifampin
NCT03928327Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- May 2019
- Primary completion
- Aug 2019
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of mobocertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-time Curve From Time 0 to Infinity and 1 more. Started May 2019; status: completed.
02
Drugs
mobocertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03928327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03928327.